Lung Cancer

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies.

Adding bevacizumab (Avastin) to a standard chemotherapy doublet reduced the risk of death by 24% and disease progression by 39% in patients with malignant pleural mesothelioma.

Ramaswamy Govindan, MD, medical oncologist, Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

Everett E. Vokes, MD, chair, Department of Medicine, investigator of head and neck and lung cancer, University of Chicago, discusses a plenary session that covered prevention and screening at the 16th World Conference on Lung Cancer.

James Stevenson, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute (TCI), discusses the impact of a stage IV non-small-cell lung cancer (NSCLC) care pathway on front-line and maintenance chemotherapy.

Nivolumab (Opdivo) has received an FDA priority review designation for patients with previously treated nonsquamous non–small cell lung cancer.

ASCO has updated their clinical practice guideline for the treatment of patients with stage IV non-small cell lung cancer, placing greater emphasis on the selection of targeted therapies.

New drug candidate necitumumab, which is being reviewed by the FDA as a treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, received a low cost-effectiveness evaluation in a study published in JAMA Oncology.

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.